Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2012.10.020PMID 23103905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

  2012cited by this paper
• Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

  2012cited by this paper
• Clinical implications of variations in anti‐infliximab antibody levels in patients with inflammatory bowel disease

  2012cited by this paper
• Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators

  2011cited by this paper
• Assessing Response and Loss of Response to Biological Therapies in IBD

  2011cited by this paper
• Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

  2010cited by this paper
• Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

  2010cited by this paper
• Infliximab, azathioprine, or combination therapy for Crohn's disease.

  2010cited by this paper
• The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

  2010cited by this paper
• Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.

  2010cited by this paper
• Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines

  2008cited by this paper
• Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

  2008cited by this paper
• Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial

  2008cited by this paper
• Paper alert

  2008cited by this paper
• A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease

  2008cited by this paper
• Infliximab dose intensification in Crohn's disease

  2007cited by this paper
• EDITOR’S QUIZ: GI SNAPSHOT

  2007cited by this paper
• Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab

  2007cited by this paper
• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

  2004cited by this paper
• CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

  2003cited by this paper
• CD 28-dependent Rac 1 activation is the molecular target of azathioprine in primary human CD 4 + T lymphocytes

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Fc-gamma receptors type3A (rs396991) genotyping for predicting infliximab efficacy and immunogenicity in ulcerative colitis: An observational study of Iraqi cohort.

  2026cites this paper
• Clinical outcomes of long-term infliximab treatment for 15 years in patients with Crohn's disease: a retrospective study.

  2026cites this paper
• Management of Anti-drug Antibodies Against TNF-Inhibitors in Sarcoidosis Patients.

  2025cites this paper
• Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease.

  2025cites this paper
• Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development

  2024cites this paper
• Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus

  2024cites this paper
• The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study

  2024cites this paper
• What Happens to Patients with Inflammatory Bowel Disease Who Are Intolerant to Thiopurines?

  2024cites this paper
• Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis

  2024cites this paper
• Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model

  2024cites this paper
• Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.

  2024cites this paper
• Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease.

  2023cites this paper
• The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD

  2023cites this paper
• Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.

  2023cites this paper
• Therapeutic Antibodies in Medicine

  2023cites this paper
• Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study

  2023cites this paper
• Morbus Crohn Update

  2023cites this paper
• Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies

  2023cites this paper
• Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?

  2023cites this paper
• Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease

  2023cites this paper
• Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease

  2023influential citation
• Oral Biologics Therapy For Inflammation Bowel Disease : A Review

  2023cites this paper
• Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease

  2023cites this paper
• The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis

  2022cites this paper
• Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis

  2022cites this paper
• A Retrospective Analysis of Clinical Features and Treatment of the Inflammatory Bowel Disease in China

  2022cites this paper
• Updates in therapeutic drug monitoring in inflammatory bowel disease

  2022cites this paper
• Monitoring of infliximab treatment in inflammatory bowel diseases – basic knowledge and current data based on clinical trials in a population of Polish patients

  2022cites this paper
• Therapeutic Drug Monitoring in Practice for Inflammatory Bowel Disease

  2022cites this paper
• Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease.

  2022cites this paper
• Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

  2022cites this paper
• The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis

  2022cites this paper
• Enhancing the Response Rate to Recombinant Uricases in Patients with Gout

  2022cites this paper
• Azatioprin u liječenju bolesnika s ulceroznim kolitisom

  2022cites this paper
• Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response

  2022cites this paper
• Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

  2022cites this paper
• NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn’s disease patients treated by combination treatment with infliximab and azathioprine

  2022cites this paper
• Medical Treatment Options for Ulcerative Colitis

  2022cites this paper
• Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

  2022cites this paper
• Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications

  2022cites this paper
• A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease.

  2022cites this paper
• The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review.

  2021cites this paper
• The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases

  2021cites this paper
• Biologic Drugs for the Treatment of Noninfectious Uveitis.

  2021cites this paper
• 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future

  2021cites this paper
• Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy.

  2021cites this paper
• A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

  2021cites this paper
• Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

  2021cites this paper
• The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease

  2021influential citation
• How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?

  2021cites this paper
• A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease

  2021cites this paper
• Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  2021cites this paper
• Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

  2021influential citation
• Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study

  2021cites this paper
• Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN

  2021cites this paper
• The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric Population for Preventing Infusion-Related Reactions to Infliximab

  2021cites this paper
• High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases

  2021cites this paper
• ECCO topical review: Refractory IBD.

  2021cites this paper
• First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus

  2020cites this paper
• Infliximab pharmacokinetics monitoring in inflammatory bowel disease.

  2020cites this paper
• Intermittent Appearance of Antibodies to Infliximab Is Not Associated With Reduced Efficacy in Patients With Inflammatory Bowel Diseases

  2020cites this paper
• Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.

  2020cites this paper
• Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn’s disease

  2020cites this paper
• Safety of hydrocortisone premedication discontinuation in patients with inflammatory bowel disease on maintenance therapy with Infliximab: a prospective clinical and pharmacological study.

  2020cites this paper
• Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar

  2020cites this paper
• Knee Joint Swelling at Presentation: A Case of Pediatric Crohn Disease With a TNFAIP3 Mutation

  2020cites this paper
• Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series

  2020cites this paper
• Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

  2020cites this paper
• Biological Therapy in Pediatric Age.

  2020cites this paper
• Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.

  2020cites this paper
• Biologics Targeting in the Treatment of Inflammatory Bowel Disease: A Conundrum

  2020cites this paper
• Infliximab levels and antibodies in IBD-related peripheral arthralgia

  2020cites this paper
• Epidemiology and natural history of paediatric-onset inflammatory bowel disease in Scotland

  2020cites this paper
• Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.

  2020cites this paper
• What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?

  2020cites this paper
• Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review.

  2020cites this paper
• Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis

  2020influential citation
• Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial

  2020cites this paper
• Optimizing Anti-tumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease with Therapeutic Drug Monitoring.

  2020cites this paper
• PREDICTORS OF INFLIXIMAB TROUGH CONCENTRATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS USING A REPEATED MEASURES DESIGN.

  2020cites this paper
• Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials

  2020cites this paper
• Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.

  2020cites this paper
• Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn’s Disease: A Retrospective Study

  2020cites this paper
• Identification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing.

  2020cites this paper
• Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study

  2020cites this paper
• Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease using Dried Blood Samples.

  2020cites this paper
• Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments

  2020cites this paper
• Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis

  2019influential citation
• Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

  2019cites this paper
• Letter: put on your thinking cap – tenofovir disoproxil fumarate for the prevention of vertical transmission of hepatitis B virus

  2019cites this paper
• Anti-TNF Combination Therapy in Inflammatory Bowel Disease: de novo or selective?

  2019cites this paper
• Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy.

  2019cites this paper
• Letter: double‐dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply

  2019cites this paper
• High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease

  2019cites this paper
• Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease

  2019cites this paper
• British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

  2019cites this paper
• Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab

  2019cites this paper
• The Evolving Role of Thiopurines in Inflammatory Bowel Disease

  2019cites this paper
• Current Medical Therapies for Ulcerative Colitis

  2019cites this paper
• Practical Aspects of Proactive TDM for Anti-TNF Agents in IBD: Defining Time Points and Thresholds to Target

  2019cites this paper